[{"address1": "2223 Avenida de la Playa", "address2": "Suite 208", "city": "LA Jolla", "state": "CA", "zip": "92037", "country": "United States", "phone": "619 400 1170", "website": "https://www.gribio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase II clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 for the treatment of primary sclerosing cholangitis, and GRI-0729, which are in pre-clinical development. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.", "fullTimeEmployees": 4, "maxAge": 86400, "priceHint": 4, "previousClose": 2.51, "open": 2.4803, "dayLow": 2.46, "dayHigh": 3.0, "regularMarketPreviousClose": 2.51, "regularMarketOpen": 2.4803, "regularMarketDayLow": 2.46, "regularMarketDayHigh": 3.0, "volume": 290657, "regularMarketVolume": 290657, "averageVolume": 46245, "averageVolume10days": 156825, "averageDailyVolume10Day": 156825, "bid": 2.63, "ask": 2.67, "bidSize": 100, "askSize": 100, "marketCap": 1351522, "fiftyTwoWeekLow": 2.46, "fiftyTwoWeekHigh": 519.61, "fiftyDayAverage": 4.7809553, "twoHundredDayAverage": 42.70801, "currency": "USD", "enterpriseValue": -3166682, "floatShares": 279605, "sharesOutstanding": 508091, "sharesShort": 1871, "sharesShortPriorMonth": 1404, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0064, "heldPercentInsiders": 0.02023, "heldPercentInstitutions": 0.035469998, "shortRatio": 0.2, "shortPercentOfFloat": 0.0066000004, "impliedSharesOutstanding": 290345, "bookValue": 11.379, "priceToBook": 0.23376396, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -12774000, "trailingEps": -51.95, "lastSplitFactor": "1:13", "lastSplitDate": 1718668800, "enterpriseToEbitda": 0.263, "52WeekChange": -0.9939355, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GRI", "underlyingSymbol": "GRI", "shortName": "GRI Bio, Inc.", "longName": "GRI Bio, Inc.", "firstTradeDateEpochUtc": 1612967400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2a4b9e2e-4254-393c-ba83-44e16bef237a", "messageBoardId": "finmb_136941170", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.66, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 4091000, "totalCashPerShare": 14.09, "ebitda": -12040000, "totalDebt": 152000, "quickRatio": 2.435, "currentRatio": 2.636, "debtToEquity": 5.432, "returnOnAssets": -2.79417, "freeCashflow": -6710500, "operatingCashflow": -10614000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]